Lykos Therapeutics

Lykos Therapeutics is proud to join the Association for Prescription Psychedelics (APP). We hope the APP will raise awareness for the need to increase federal research funding for treatments, and the potential benefits to patients suffering from mental health conditions if these medicines are approved by the FDA and safely integrated into our healthcare system. We’re excited to continue doing all we can to develop safe, effective and accessible prescription psychedelic medicine. For more information about the APP see here https://lnkd.in/eguwYNMr

According to the National Center for PTSD, seven out of 100 veterans experience #PTSD in their lifetime. Depending on their era of service, the number of veterans who had PTSD in their lifetime could be as high as 29%. (bit.ly/4fA1cnY) This #VeteransDay, we honor the service and sacrifice of each and every Veteran at home and abroad. We will continue to work tirelessly to bring new, innovative treatments for them and for every American struggling with PTSD. 

Read the latest statement from Lykos Therapeutics on our recent FDA meeting here: https://lnkd.in/eN7AjHmV

We are proud to congratulate our Chief Scientific Officer, Berra Yazar-Klosinski, Ph.D., on receiving the Mental Health Hero award last weekend for innovative research on PTSD treatment. The event was hosted by Assemblymember Gail Pellerin in recognition of Suicide Prevention Month. Lykos is committed to bringing groundbreaking new treatment to the 13 million Americans who live with PTSD. https://lnkd.in/gCV5N_Gf

Today, we announce changes to the executive team. Amy Emerson will step down as CEO; Lykos COO, Michael Mullette, will serve as the interim CEO and Dr. David Hough will assume the role of CMO. We thank Amy for her leadership over the past decade and look forward to the future of working with the FDA to bring this potential new option to people living with PTSD. https://lnkd.in/eBYSZt2z

Today, we announce our decision to reorganize Lykos Therapeutics in effort to focus on addressing FDA’s recent decision on our investigational treatment option for adults with PTSD. Learn more here: https://lnkd.in/eeBSTyfP

Thank you American Psychological Association, for hosting another educational and collaborative event! We were thrilled to connect with everyone and share more about our mission to help adults living with #PTSD. #APA2024

We remain steadfast in our commitment to working with the FDA to bring this potential new therapy to patients. Read our full announcement here: https://lnkd.in/eYbSbEuE

In #Seattle for this year’s #APA2024? We’re here too! Visit our team at booth #315 to learn more about the neurobiology of #PTSD.  

Today, we announce new initiatives and measures for additional oversight for midomafetamine capsules in combination with psychological intervention (“midomafetamine-assisted therapy”) for the treatment of #PTSD in adults, if approved by the FDA: - Establishing an independent advisory board   - Working with top behavioral health facilities   - Collaborating with others on training    Learn more about our dedication to patient safety here: https://lnkd.in/ePzQa66U